Clinical Trial: Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion.

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482605) titled 'Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion.' on Feb. 26.

Brief Summary: This study aims to prospectively and multi-centrally explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy in treating NSCLC participants with EGFR mutations and malignant pleural effusion, thereby providing more evidence-based medical evidence for improved diagnosis and treatment of NSCLC-MPE participants . Additionally, NGS testing of ctDNA from peripheral blood will be performed before the first furmonertinib treatment, before the first thoracic radiotherapy and after its completion, and after...